Staying informed on the latest in cachexia, sarcopenia, and wasting disorders research is essential yet challenging. The SCWD Digest offers concise updates and expert insights into significant studies and developments. We highlight and link directly to leading research, making it easier for healthcare professionals to access and apply groundbreaking findings. Our goal: empower the medical community to advance patient care worldwide efficiently.
Parkinson's disease (PD) increases fracture risk owing to postural instability and bone fragility, with femur fractures being the most frequent and clinically significant. Many patients with PD experience weight loss as the disease progresses, and low body mass index (BMI)...
Sarcopenia is defined as the loss of muscle mass, strength, and/or performance. It is strongly associated with all-cause mortality. Fibroblast growth factor 23 (FGF23) is markedly elevated in patients with chronic kidney disease, especially those receiving maintenance dialysis. FGF23 has...
Effective treatments for skeletal muscle atrophy, a debilitating condition linked to ageing and glucocorticoid therapy, remain lacking. Zinc finger BED-type containing 6 (ZBED6), a transcriptional repressor, enhances muscle growth and protects against sepsis-induced atrophy, but its role in ageing- and...
While multidomain interventions show promise for promoting healthy aging, their impact on brain structure remains unclear. This randomized controlled trial (ENHANCE) assessed the efficacy of a 12-month group-based multidomain intervention on brain structure and function in community-dwelling older adults, with...
Heart failure with preserved ejection fraction (HFpEF) is associated with exercise intolerance, accompanied by alterations in the peripheral skeletal muscle (SKM). We have recently shown that titin, a giant sarcomere protein, is hyperphosphorylated in HFpEF. MuRF1 is a muscle-specific ubiquitin...
Sarcopenia represents a major clinical and societal challenge facing rapidly aging populations. Accessible and specific biomarkers represent valuable tools, both in diagnosis and assessing the efficacy of therapeutic interventions. C-terminal agrin fragment (CAF) is the most commonly used blood-based biomarker...
Androgen deprivation therapy (ADT) increases the risk of adverse cardiovascular events in patients with prostate cancer. ADT can induce body composition change; however, the association between body composition change and cardiovascular outcomes remains unclear. This study aimed to determine the...
Sarcopenia has been linked to poor outcomes in various cancers, but its specific effect on sarcoma patients remains unclear. This systematic review and meta-analysis investigates the impact of sarcopenia, estimated using CT, on sarcoma patients, focusing on prognostic implications and...
Radiologically defined sarcopenia (RS), defined as a lack of skeletal muscle mass (SMM) measured on cross-sectional CT or MR imaging, is increasingly recognized as a significant prognostic determinant in head and neck cancer (HNC). A systematic literature search of Embase...
The decline in skeletal muscle mass and muscle strength linked to aging, also known as sarcopenia, is strongly associated with disability, traumatic injury, and metabolic disease in patients. Meanwhile, sarcopenia increases the risk of adverse orthopedic perioperative complications including implant...
Sarcopenia, a progressive loss of muscle mass and function, increases health risks in older adults, especially in rapidly ageing populations like Korea. Computed tomography (CT) imaging at the third lumbar vertebra (L3) level is a gold standard for assessing skeletal...
